PharmAthene Presents Data For SparVax(TM), A Novel Vaccine For The Prevention And Treatment Of Anthrax Infection
PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced that results from a second Phase II study of SparVax(TM) were presented yesterday at the 12th Annual Conference on Vaccine Research, being held in Baltimore, MD, April 27-29, 2009. The conference is sponsored by the National Foundation of Infectious Diseases. David P.
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment